One or more fractures were reported by 19 (1.0%) participants across the tirzepatide groups and by eight (1%) participants in the placebo group
During the first month of treatment, as your body slowly acclimates to the newly introduced medication, you might notice only small shifts in your daily eating habits
Insurance plans usually cover tirzepatide (Mounjaro) for the management of type 2 diabetes mellitus in adults, but often do not cover tirzepatide (Zepbound) for weight loss and require prior authorization before approval
Novos general counsel John Kuckelman told CNBC it may have been accurate for Lilly to boast about Zepbounds greater efficacy before the 7.2 milligram dose of Wegovy became available, but it is no longer accurate to say that. Novos suit says Lilly acknowledges a higher dose of Wegovy in a brief footnote in the television ad, but it says the footnote is ambiguous, confusing, virtually illegible, and wholly inadequate. key background Novo Nordisk and Eli Lilly, chief rivals in the booming GLP-1 industry, have struggled for dominance over the obesity medication market, with Novos market share slipping from an early lead